Modulatable switch for selection of donor modified cells
AssigneesCalimmune, Inc., Calimmune Australia Pty Ltd
InventorsChristopher Walter ALMA, Jeffrey BARTLETT, Louis Randall BRETON, Geoffrey Phillip SYMONDS, Ming YAN
Life of this patent
Estimating the term…
Abstract
The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells.
Claims20
A method of providing benefits of a lymphocyte infusion to a patient in need of treatment thereof comprising:
- (a) generating HPRT deficient lymphocytes from a donor sample;
- (b) positively selecting for the HPRT deficient lymphocytes ex vivo to provide a population of modified lymphocytes;
- and
- (c) administering the population of modified lymphocytes to the patient following an administration of an HSC graft to the patient.
A method of treating a hematological cancer in a patient in need of treatment thereof comprising:
- (a) generating HPRT deficient lymphocytes from a donor sample;
- (b) positively selecting for the HPRT deficient lymphocytes ex vivo to provide a population of modified lymphocytes;
- (c) inducing at least a partial graft versus malignancy effect by administering an HSC graft to the patient;
- and
- (d) administering the population of modified lymphocytes to the patient following the detection of residual disease or disease recurrence.
A method of treating cancer in a patient in need of treatment thereof comprising:
- (a) generating CAR-T cells that include an antitumor chimeric receptor and which are HPRT deficient;
- (b) positively selecting for the HPRT deficient CAR-T cells ex vivo to provide a population of CAR-T cells for administration;
- and
- (c) administering the population of CAR-T cells to the patient.
Dependencies are inferred from the claim text.